InterMune Reports Third Quarter 2009 Financial Results and Business ...(marks of Roche. Financial tables foll...),Health

Financial tables follow

                                InterMune, Inc.
          PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
              (unaudited, in thousands, except per share amounts)

                                  Three Months Ended   Nine Months Ended
                                      September 30        September 30
                                      ------------        ------------
                                     2009      2008*     2009      2008*
                                     ----      ----      ----      ----
      Revenue, net
        Actimmune                  $6,493    $7,505   $19,635   $23,297
        Collaboration revenue      20,818    15,818    22,454    17,454
                                   ------    ------    ------    ------
          Total revenue, net       27,311    23,323    42,089    40,751

      Costs and expenses:
        Cost of goods sold          1,019     1,413     5,737     7,276
        Research and
         development               20,608    25,618    67,965    78,028
        General and
         administrative             9,916     8,205    26,911    22,744
        Acquired research and
        development milestones      1,750         -    15,250         -
        Restructuring charges          55         -       795         -
                                       --        --       ---        --
          Total costs and
           expenses                33,348    35,236   116,658   108,048

      Loss from operations         (6,037)  (11,913)  (74,569)  (67,297)

      Interest income                 331     1,212     1,498     4,644
      Interest expense             (2,714)   (2,971)   (7,934)  (10,067)
      Loss on extinguishment
       of debt                       (724)        -   (10,264)   (1,294)
      Other income (expense)          396        18     6,043     1,286
                                      ---        --     -----    
'/>"/>
SOURCE  InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 
Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3